Gout Therapeutics Market

Gout Therapeutics Market by Drugs (Colchicine, Corticosteroids, Non-steroidal Anti-inflammatory Drugs, Urate-lowering Drugs, and Others), Diseases (Chronic Gout and Acute Gout), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-2295
  • Author: Growth Market Reports
  • Rating: 4.8
  • Total Reviews: 3
  • No. Of Pages: 213
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global gout therapeutic market size is estimated to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing biologics usage and growing R&D activities on regenerative drug as well as advanced technology in imaging modalities. Moreover, the high prevalence of gout caused by excessive alcohol consumption presents a key insight of the market expansion.

Gout is a severe form of arthritis that causes joint pains in several body parts including feet, ankles, kneels, wrists, heels, hands, and elbows. Redness, severe pain, and soreness in the joints are some of the main symptoms of gout. There are a variety of treatment options available in the market for gout and these treatments aid in lowering uric acid levels in the body as well as improving the kidneys' ability to eliminate uric acid through urine. According to the Australian Bureau of Statistics and the National Health Survey 2017-2018, there were 187,000 people suffering from gout in Australia, which was around 0.8% of the total population of the country. Moreover, males are more likely to develop gout than females.

The COVID-19 pandemic outbreak has resulted in unforeseen consequences such as significant delays in disease detection and treatment. On the other hand, hospitals and healthcare services were drastically curtailed owing to quarantine and social distancing precautions imposed by several governments worldwide. In addition, the COVID-19 pandemic had a significant adverse impact on the functioning of hospital treatment for non COVID-19 patients in hospitals.

Market Trends, Drivers, Restraints, and Opportunities

  • Improvement in the area of biologics and growing implementation of these drugs based on their ability to produce powerful anti-inflammatory action are expected to boost the market growth.
  • Rising consumption of certain medications such as diuretics, changing lifestyle pattern and increasing geriatric population are another factor fueling the market expansion.
  • Increasing number of product approvals along with private & public funding are some of the factors surging the market growth.
  • Expiring robust product patent, highly competitive key players in the generic drug sector, and high cost associated in newly launched drugs are likely to hamper the market growth in the coming years.
  • Focusing on regenerative drugs and the preference for combination therapy are projected to create numerous opportunity for the market growth in the near future.

Scope of the Report                 

The report on the global gout therapeutic market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Gout Therapeutic Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Drugs (Colchicine, Corticosteroids, Non-steroidal Anti-inflammatory Drugs, Urate-lowering Drugs, and Others), and Diseases (Chronic Gout and Acute Gout)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Lannett Co.; GlaxoSmithKline plc.; Novartis AG; Regeneron Pharmaceuticals;  AstraZeneca plc; Merck & Co. Inc.; Teijin Pharma Ltd.; Horizon Therapeutics plc.;  Mylan, and Takeda Pharmaceutical Co. Ltd.

Market Segment Insights

Nonsteroidal anti-inflammatory drugs segment is expected to grow at a rapid pace

Based on drugs, the global gout therapeutic market is segmented into colchicine, corticosteroids, non-steroidal anti-inflammatory drugs, urate-lowering drugs, and others. The nonsteroidal anti-inflammatory drugs segment is expected to grow at a rapid pace in the coming years due to the high level of medicine penetration, low cost in contrast to other classes of pharmaceuticals, and the capacity to reduce pain in the event of a severe gout attack.

On the other hand, the urate-lowering drugs segment is projected to account for a large market share during the projected period as the uric acids are wide used as the most popular alternative therapy. Xanthine oxidase inhibitors such as allopurinol and febuxostat, and uricosuric medicines such as benzbromarone, probenecid, and sulfinpyrazone are some of the most commonly used drugs in this segment.


Gout Therapeutics Market

Chronic gout segment is projected to expand at a considerable CAGR

On the basis of diseases, the market is bifurcated into chronic gout and acute gout. The chronic gout segment is projected to expand at a considerable CAGR during the targeted period due to the growing commercialization of various drugs for chronic conditions. Furthermore, urate-lowering medicines such as xanthine oxidase inhibitors and uricosuric agents are included in this segment. Colchicine, non-steroidal anti-inflammatory drugs (NSAIDs), and corticosteroids are used in the acute phase. When compared to chronic therapies, this segment is estimated to gain a smaller share in the market due to low-cost medications, poor treatment adherence, and the drugs' ability to ease pain for a shorter amount of time.


Gout Therapeutics Market

North America is anticipated to constitute a key market share

In terms of regions, the global gout therapeutic market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a key market share in the coming years due to the presence of well-established market players, urate lowering agents, and expansive early stage introduction of medicines. Moreover, affordability for highly expensive biologics and presence of large patient base especially in the US present another key driver of the regional market growth. Gout is most common problems in North American countries, affecting around 8.3 million individuals alone in the US with a prevalence of the disease around 1–4% of the total population. Some of the major factors such as government initiatives to provide improved healthcare services to all citizens, advantageous reimbursement, existence of significant players, and increased adoption of high-cost therapies are fueling the market growth in the region.

The market of Asia Pacific, however, is expected to expand at a robust growth rate during the forecast period owing to the factors such as diverse patient pool as well as increased investment by big companies in local industries and hospital networks. With the existence of multiple high-growth economies such as India, China, South Korea, and other South Asian countries, the region is anticipated to witness a substantial market growth.


Gout Therapeutics Market

Segments

Segments Covered in the Report

The global gout therapeutic market has been segmented on the basis of

Drugs

  • Colchicine
  • Corticosteroids
  • Non-steroidal Anti-inflammatory Drugs
  • Urate-Lowering Drugs
  • Others

Diseases

  • Chronic Gout
  • Acute Gout

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Lannett Co.
  • GlaxoSmithKline plc.
  • Novartis AG
  • Regeneron Pharmaceuticals
  • AstraZeneca plc
  • Merck & Co. Inc.
  • Teijin Pharma Ltd.
  • Horizon Therapeutics plc.
  • Mylan, and Takeda Pharmaceutical Co. Ltd.

Competitive Landscape

Some of the key players competing in the global gout therapeutic market are Lannett Co.; GlaxoSmithKline plc.; Novartis AG; Regeneron Pharmaceuticals; AstraZeneca plc; Merck & Co. Inc.; Teijin Pharma Ltd.; Horizon Therapeutics plc.; Mylan, and Takeda Pharmaceutical Co. Ltd.

In order to grow the client base and strengthen the market presence, companies are expanding their capabilities across regions and entering new markets in developing countries. The primary marketing strategies followed by major players in the region include collaborations and acquisitions of well-established firms in the market as well as the development of innovative products. For example, Horizon Pharma plc acquired Crealta Holdings LLC in December 2015 with the goal of expanding its orphan business sector and improving rheumatic knowledge and infrastructure. In another event, AstraZeneca and Ironwood Pharmaceuticals signed a licensing agreement in April 2016 that gave the latter company an exclusive rights to Zurampic (lesinurad) in the US. The collaboration was likely to ensure Zurampic's successful advancement in the US.

Gout Therapeutics Market

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Gout Therapeutics Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Gout Therapeutics Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Gout Therapeutics Market - Supply Chain
  4.5. Global Gout Therapeutics Market Forecast
     4.5.1. Gout Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Gout Therapeutics Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Gout Therapeutics Market Absolute $ Opportunity
5. Global Gout Therapeutics Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Gout Therapeutics Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Gout Therapeutics Demand Share Forecast, 2019-2026
6. North America Gout Therapeutics Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Gout Therapeutics Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Gout Therapeutics Demand Share Forecast, 2019-2026
7. Latin America Gout Therapeutics Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Gout Therapeutics Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Gout Therapeutics Demand Share Forecast, 2019-2026
8. Europe Gout Therapeutics Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Gout Therapeutics Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Gout Therapeutics Demand Share Forecast, 2019-2026
9. Asia Pacific Gout Therapeutics Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Gout Therapeutics Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Gout Therapeutics Demand Share Forecast, 2019-2026
10. Middle East & Africa Gout Therapeutics Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Gout Therapeutics Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Gout Therapeutics Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Gout Therapeutics Market: Market Share Analysis
  11.2. Gout Therapeutics Distributors and Customers
  11.3. Gout Therapeutics Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)

Segments Covered in the Report

The global gout therapeutic market has been segmented on the basis of

Drugs

  • Colchicine
  • Corticosteroids
  • Non-steroidal Anti-inflammatory Drugs
  • Urate-Lowering Drugs
  • Others

Diseases

  • Chronic Gout
  • Acute Gout

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Lannett Co.
  • GlaxoSmithKline plc.
  • Novartis AG
  • Regeneron Pharmaceuticals
  • AstraZeneca plc
  • Merck & Co. Inc.
  • Teijin Pharma Ltd.
  • Horizon Therapeutics plc.
  • Mylan, and Takeda Pharmaceutical Co. Ltd.

Some of the key players competing in the global gout therapeutic market are Lannett Co.; GlaxoSmithKline plc.; Novartis AG; Regeneron Pharmaceuticals; AstraZeneca plc; Merck & Co. Inc.; Teijin Pharma Ltd.; Horizon Therapeutics plc.; Mylan, and Takeda Pharmaceutical Co. Ltd.

In order to grow the client base and strengthen the market presence, companies are expanding their capabilities across regions and entering new markets in developing countries. The primary marketing strategies followed by major players in the region include collaborations and acquisitions of well-established firms in the market as well as the development of innovative products. For example, Horizon Pharma plc acquired Crealta Holdings LLC in December 2015 with the goal of expanding its orphan business sector and improving rheumatic knowledge and infrastructure. In another event, AstraZeneca and Ironwood Pharmaceuticals signed a licensing agreement in April 2016 that gave the latter company an exclusive rights to Zurampic (lesinurad) in the US. The collaboration was likely to ensure Zurampic's successful advancement in the US.

Gout Therapeutics Market

Buy Report